CoChat

Evaluation of the Predictive Value of a Clinical Worsening Definition Using 2-Year Outcomes in Patients With Pulmonary Arterial Hypertension

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Background Time to clinical worsening has been proposed as a primary end point in clinical trials of pulmonary arterial hypertension (PAH); however, neither standardized nor validated definitions of clinical worsening across PAH trials exist. This study aims to evaluate a proposed definition of clinical worsening within a large prospective, observational registry of patients with PAH with respect to its value as a predictor of proximate (within 1 year) risk for subsequent major events (ie, death, transplantation, or atrial septostomy). Methods We assessed overall 2-year survival and survival free from major events to determine the relationship between clinical worsening and major events among adults with hemodynamically defined PAH (N = 3,001). Freedom from clinical worsening was defined as freedom from worsening functional class (FC), a ≥ 15% reduction in 6-min walk distance (6MWD), all-cause hospitalization, or the introduction of parenteral prostacyclin analog therapy. Results In the 2 years of follow-up, 583 patients died. Four hundred twenty-six died after a documented clinical worsening event, including FC worsening (n = 128), a ≥ 15% reduction in 6MWD (n = 118), all-cause hospitalization (n = 370), or introduction of a prostacyclin analog (n = 91). Patients who experienced clinical worsening had significantly poorer subsequent 1-year survival postworsening than patients who did not worsen (P Conclusions Clinical worsening was highly predictive of subsequent proximate m…

Overview

Integrity signals

Registry

Crossref · 10.1378/chest.12-3023

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Cited by

See all 93

Metadata

Authors
Frost, A. E., Badesch, D. B., Miller, D. P., Benza, R. L., Meltzer, L. A., & McGoon, M. D.
Affiliations
  • Baylor College of Medicine (US)
  • University of Colorado Denver (US)
  • Allegheny General Hospital (US)
  • Actelion (United States) (US)
  • Mayo Clinic (US)
Corresponding author
Frost, Adaani E.
Venue
Chest
Publisher
Elsevier BV
Published
2013-11
Volume
144
Issue
5
Pages
1521-1529
ISSN
0012-3692 (ISSN-L)
OpenAlex
W2085328300
Cited by
90
References
30
Citations by year
2026: 2 · 2025: 6 · 2024: 6 · 2023: 5 · 2022: 8 · 2021: 5 · 2020: 6 · 2019: 15 · 2018: 10 · 2017: 5 · 2016: 8 · 2015: 6 · 2014: 7 · 2013: 1
FWCI
5.96
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • CHEST Journal (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Bayer
  • Biogen
  • United Therapeutics Corporation
  • IC Design Education Center
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
pulmonary arterial hypertension, clinical deterioration, primary endpoint, survival, mortality, functional class, 6-minute walk distance, hospitalization, lung transplantation, atrial septostomy, clinical trial endpoints
MeSH terms
Antihypertensive Agents, Exercise Test, Female, Follow-Up Studies, Hemodynamics, Humans, Hypertension, Pulmonary, Male, Middle Aged, Prognosis, Prospective Studies, Epoprostenol, Registries, Time Factors, United States, Survival Rate, Disease Progression, Disease Management, Familial Primary Pulmonary Hypertension

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of the Predictive Value of a Clinical Worsening Definition Using 2-Year Outcomes in Patients With Pulmonary Arterial Hypertension. https://app.cochat.ai/papers/10.1378/chest.12-3023
The paper
Frost, A. E., Badesch, D. B., Miller, D. P., Benza, R. L., Meltzer, L. A., & McGoon, M. D. (2013). Evaluation of the Predictive Value of a Clinical Worsening Definition Using 2-Year Outcomes in Patients With Pulmonary Arterial Hypertension. Chest. https://doi.org/10.1378/chest.12-3023

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.